Users Stopping Anti-Obesity Jabs Regain Pounds at a Quadrupled Rate Compared to Dieters

New research reveals that people who stop using popular slimming jabs like semaglutide or tirzepatide may regain shed pounds at a significantly accelerated pace than those who halt traditional lifestyle regimens.

Published data in a prominent medical journal demonstrates that while overweight individuals frequently drop substantial amounts of their body weight while using the jabs, the mass is regained at an average rate of 0.8 kg per month upon discontinuation.

"Individuals using such drugs should be cognizant of the potential of quick weight regain when the treatment ends," cautioned lead investigator Dr. Susan Jebb.

That rate of regain means a return to pre-treatment weight within about one and a half years.

Analyzing Treatments

The study, which examined dozens of trials involving over 9,000 of patients, compared the results of these new drugs with other pills.

Researchers note that people who shed pounds through lifestyle changes alone typically experience a less rapid weight regain—around 100 grams monthly—once they finish.

Explaining the Fast Rebound

Nutrition scientists suggest the way of the injections is key to understanding the amplified regain.

The injections copy a natural hormone called GLP-1, which moderates appetite.

"Long-term administration of the hormone levels several times higher than normal may cause the system to produce less of its endogenous GLP-1, and may also lessen responsiveness to its actions," explained Dr. Adam Collins, a dietetics expert.

"Withdrawal of this GLP-1 'fix' means hunger is no longer kept in check, making excessive eating much more probable."

A Lifelong Condition?

Health authorities recommend the jabs for individuals with weight-linked health risks, accompanied by prescribed lifestyle changes.

A number of clinicians contend that, considering the significant potential of relapse, the treatment is often ongoing.

This perspective is reinforced by pharmaceutical companies, who state that the findings "underscore the chronic character of obesity," comparing it to managing diseases like hypertension.

Patient Experiences

People who have come off the medication describe a powerful resurgence of hunger.

"I experienced something that goes on and I was suddenly ravenous," said a patient.

The struggle is exacerbated if users have not adopted permanent lifestyle or habit changes during therapy.

Significant Interest

Survey data suggest that a significant number of people in the UK have tried weight-loss jabs in the last 12 months, with demand being substantial.

• Use is higher among women compared to males.
• The middle-aged age group shows the greatest usage rates.
• A large proportion obtain the drugs through private healthcare rather than the NHS.

In conclusion, researchers caution that while GLP-1 drugs are potent tools for shedding pounds, they are not a magic cure and long-term success hinges on ongoing lifestyle support.